Late-breaking data from the LIFE-BTK clinical trial evaluating the Esprit™ BTK in people with chronic limb-threatening ischemia.
Abbott today announced late-breaking data from the LIFE-BTK clinical trial evaluating the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System (Esprit BTK) in people with chronic limb-threatening ischemia (CLTI). CLTI is a severe stage of peripheral artery disease (PAD) due to…